USD 40.80 Billion
Report ID:
SQMIG35A2547 |
Region:
Global |
Published Date: February, 2024
Pages:
157
|Tables:
65
|Figures:
75
Global mRNA Therapeutics Market size was valued at USD 40.80 Billion in 2022 and is poised to grow from USD 41.62 Billion in 2023 to USD 48.76 Billion by 2031, at a CAGR of 2% during the forecast period (2024-2031).
Recently, mRNA-based therapeutics have gained traction as the potential answer to effectively treating chronic conditions. This has fed the guaranteed and consistent growth of the mRNA therapeutics market. mRNA vaccines are favored over DNA vaccines in recent times. These advantages are underscored during production and distribution, offering a safer alternative. mRNA vaccines and therapeutics have also withstood human clinical trials and come out successful. This has also driven the demand for these products.
Moderna and Pfizer-BioNTech have largely contributed to the market during the COVID-19 pandemic. Their vaccines in response to the global health crisis fueled substantial market growth. These therapeutics are also being heavily used in oncology clinical trials. In 2021, mRNA vaccine trials for cancer patients scored a great number of volunteers, coming in at the second-highest. This, though, was excluding COVID-19 trials in cancer patients. Industry growth has reached new heights since then.
New versions of the SARS-CoV-2 virus have started to crop up around the world. The need for effective vaccines has turned medical professionals to mRNA vaccines. The COVID-19 pandemic accelerated the usage of mRNA-based products, fueling further market expansion.
Messenger-RNA is an emerging therapeutic tool. This has come into light due to technological advancements that enhance translation and stability, along with delivery techniques. The pharmacological industry has also seen the potential for expansion through mRNA vaccines, increasing the potential for growth in the market.
mRNA vaccines are the next step in vaccine development. They will bring forth a new era in immunization. This can be portrayed with a fine example. Moderna Inc. and the National Institute of Allergy and Infectious Diseases joined hands in March 2020 to create mRNA-1273 (NIAID). This vaccine showed a 94.1% rate of efficacy in the prevention of symptomatic COVID-19. The US FDA granted it speedy approval and registered it for emergency use in December 2020.
In addition, the rapidly expanding field of mRNA therapeutics is poised to revolutionize personalized medicine. It will remodel the traditional standards of healthcare , which will raise the demand for mRNA-based products in the near future.
Global Market Size
USD 40.80 Billion
Largest Segment
Infectious Diseases
Fastest Growth
Oncology
Growth Rate
2% CAGR
To get more reports on the above market click here to Buy The Report
The global mRNA therapeutics market is segmented on the basis of type, application, region. By type, the market is segmented into prophylactic vaccines, therapeutic vaccines, therapeutic drugs. By application, the mRNA therapeutics market is segmented into rare genetic diseases, oncology, respiratory diseases, infectious diseases, others. By end–use, the market is segmented into hospitals & clinics, research organizations, others. By region, the mRNA therapeutics market is segmented into North America, Europe, Latin America, Asia- Pacific, Middle East and Africa.
mRNA Therapeutics Market Analysis By Application
By application type, there is one market segment that brought in 100% of the revenue in the market in 2022. This category is infectious disease. Infectious diseases have held dominance over the market for a long time and there are a number of reasons supporting its supremacy. The rising integration of mRNA in vaccines has cemented this segment’s position. Other factors responsible are the wide impact of the COVID-19 pandemic and an increase in the number of volunteers opting for clinical trials targeting different infectious diseases. All of this has sustained its growth in the market with the potential to grow further.
Infectious disease may lead the market, but the oncology segment is quickly gaining ground. According to WHO, cancer killed nearly 10 million in 2020. The oncology illness is the no.1 cause for mortality globally. This fact has driven the importance of effective medications against cancer. The prevalent forms of this disease are breast, colon, rectum, lug, stomach, and liver. These are the most fatal variants of the disease and also the most common. The rising incidence of this segment’s illness has boosted the need for mRNA-based cancer vaccines and therapies. This is a potentially great step in continued market expansion.
mRNA Therapeutics Market Analysis By Type
Prophylactic vaccines have remained at the top of the market for a while. In 2022, it held an impressive 100% share of the market's revenue. This explains its constant dominance over the mRNA therapeutics market. There are constant R&D efforts furthering this segment’s expansion. At least 77% of mRNA-based businesses are currently working on one preventive vaccine, stabilizing this segment’s position. Prophylactic vaccines have gained this vast revenue figure in the COVID-19 pandemic, supplying many products during the global crisis. Other vaccines that treat conditions like RSV (respiratory syncytial virus) and influenza have also used these vaccines, contributing to this segment’s supremacy.
To get detailed analysis on other segments, Request For Free Sample Report
North America asserted its dominance in the market, holding a substantial share of over 35.0%, and is poised to emerge as the fastest-growing region in the forecast period. This ascendancy can be attributed to several key factors, including the availability of significant research funding, the expansion of federal programs dedicated to advancing RNA-based medicines, and a burgeoning number of clinical trials. A case in point is the robust support provided by institutions such as The National Institutes of Health (NIH), the Defense Department, and federally funded academic laboratories. Their unwavering backing for foundational research, including that conducted by Graham and other researchers, has played a pivotal role in the rapid development of COVID-19 vaccines. Notably, in response to the pandemic, the government injected an additional $10.5 billion into vaccine manufacturers, expediting the delivery of their products. These factors collectively underscore North America's position as a thriving hub for mRNA-based medicines and therapeutics.
Europe, on the other hand, secured the second-largest revenue share, propelled by a growing patient population and heightened awareness regarding rare genetic diseases. Additionally, Europe benefits from the presence of major industry players and a burgeoning demand for mRNA vaccines and therapeutics. As part of an expansion effort aimed at enabling the local delivery of mRNA vaccines and therapies, Moderna is extending its presence across several European countries, including Denmark, Belgium, the Netherlands, Poland, Norway, and Sweden. This strategic move is expected to substantially bolster the demand for mRNA vaccines and further fuel market growth in the region during the forecast period. Europe's evolving landscape, characterized by a blend of established industry giants and transformative treatment needs, positions it as a pivotal player in the global mRNA-based medicine arena.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
mRNA Therapeutics Market Drivers
COVID-19 Pandemic
Growing Investment and Funding
Expanding Clinical Trials
mRNA Therapeutics Market Restraints
Production and Supply Chain Challenges
Safety Concerns
Competition from Other Therapies
Request Free Customization of this report to help us to meet your business objectives.
The competitive environment of the global mRNA therapeutics market is made up of several key players. There is a mix of renowned pharmaceutical companies and rising biotech startups, along with innovative research institutes. Some industry leaders in this market are Pfizer, Moderna, CureVac, Translate Bio, BioNTech, and Arcturus Therapeutics.
Moderna and Pfizer collaborated frequently with BioNTech during the COVID-19 pandemic. They developed pioneer mRNA COVID-19 vaccines, helping fight the virus globally. This development has steeled their place at the top of the market. The market’s top dogs use their extensive expertise of the mRNA technology, along with their huge production capacity, to maintain their share of the market.
Top Player’s Company Profiles in mRNA Therapeutics Market
Recent Developments in mRNA Therapeutics Market
mRNA Cancer Vaccines:
Partnerships and Collaborations:
Orphan Diseases:
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Product types team that Collects, Collates, Correlates, and Analyzes the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
According to our analysis, the global mRNA therapeutics market has expanded due to continued innovation in the medical field. It has even given a hand in said advancements. It has achieved that with the potential of mRNA-based treatments to transform the way medicine works. The COVID-19 pandemic was a turning point for the market. The deployment of effective mRNA vaccines during that time highlighted its importance in infectious disease control.
The mRNA therapeutics landscape is changing and evolving quickly. The market can now help in the treatment of rare genetic diseases, oncology, and a number of autoimmune conditions. The healthcare sector will be disrupted by this move towards customized and specialized medication. The industry will be able to provide customized treatments, tailored to the varying genetic profiles among different patients.
Report Metric | Details |
---|---|
Market size value in 2022 | USD 40.80 Billion |
Market size value in 2031 | USD 48.76 Billion |
Growth Rate | 2% |
Base year | 2023 |
Forecast period | 2024-2031 |
Forecast Unit (Value) | USD Billion |
Segments covered |
|
Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
Companies covered |
|
Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
For the mRNA Therapeutics Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the mRNA Therapeutics Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the mRNA Therapeutics Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the mRNA Therapeutics Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Report ID: SQMIG35A2547
sales@skyquestt.com
USA +1 351-333-4748